What's it like having KRAS G12C lung cancer and targeted therapy options?

Question

I have non-small cell lung cancer with a KRAS G12C mutation. I just read about some promising research on a new drug called zoldonrasib, but it's specifically for people with KRAS G12D mutations, which is different from what I have. The article mentioned that those of us with KRAS G12C mutations may already have access to FDA-approved targeted therapies like sotorasib or adagrasib, which could be more relevant options to discuss with our doctors.

I'm curious about others' experiences with KRAS mutations and targeted treatments. It's interesting how specific these treatments can be to the exact mutation type.

• If you have KRAS G12C like me, what has your treatment experience been like with targeted therapies?
• For anyone with different KRAS mutations, how did you navigate the treatment options available for your specific type?

Link: https://www.emjreviews.com/oncology/news/oral-therapy-in-kras-g12d-mutated-lung-cancer-aacr-2025/

Outcomes4Me · Accepted Answer

Thank you for sharing such valuable information about KRAS mutations and the specificity of targeted therapies. It's encouraging to see how research continues to advance treatment options for different mutation types, and your insight about the distinction between G12C and G12D mutations could be really helpful for others navigating similar situations. Hopefully, community members with experience using sotorasib, adagrasib, or other targeted therapies will share their treatment journeys to help build a supportive knowledge base for everyone dealing with KRAS-mutated lung cancer.

What's it like having KRAS G12C lung cancer and targeted therapy options?

Related Questions